These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24520984)

  • 1. Increasing public support for supervised injection facilities in Ontario, Canada.
    Strike C; Jairam JA; Kolla G; Millson P; Shepherd S; Fischer B; Watson TM; Bayoumi AM
    Addiction; 2014 Jun; 109(6):946-53. PubMed ID: 24520984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public opinions about supervised smoking facilities for crack cocaine and other stimulants.
    Strike C; Rotondi NK; Watson TM; Kolla G; Bayoumi AM
    Subst Abuse Treat Prev Policy; 2016 Feb; 11():8. PubMed ID: 26860540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public opinion towards supervised injection facilities and heroin-assisted treatment in Ontario, Canada.
    Cruz MF; Patra J; Fischer B; Rehm J; Kalousek K
    Int J Drug Policy; 2007 Jan; 18(1):54-61. PubMed ID: 17689344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Support of supervised injection facilities by emergency physicians in Canada.
    Katz N; Leonard L; Wiesenfeld L; Perry JJ; Thiruganasambandamoorthy V; Calder L
    Int J Drug Policy; 2017 Nov; 49():26-31. PubMed ID: 28886562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Supervised injection facilities in Canada: past, present, and future.
    Kerr T; Mitra S; Kennedy MC; McNeil R
    Harm Reduct J; 2017 May; 14(1):28. PubMed ID: 28521829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding supervised injection facilities across Canada: lessons from the Vancouver experience.
    Young S; Fairbairn N
    Can J Public Health; 2018 Apr; 109(2):227-230. PubMed ID: 29981039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of supervised injection facilities and injection risk behaviours among young drug injectors.
    Bravo MJ; Royuela L; De la Fuente L; Brugal MT; Barrio G; Domingo-Salvany A;
    Addiction; 2009 Apr; 104(4):614-9. PubMed ID: 19215603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceptions about supervised injection facilities among people who inject drugs in Philadelphia.
    Harris RE; Richardson J; Frasso R; Anderson ED
    Int J Drug Policy; 2018 Feb; 52():56-61. PubMed ID: 29241143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambivalence about supervised injection facilities among community stakeholders.
    Strike C; Watson TM; Kolla G; Penn R; Bayoumi AM
    Harm Reduct J; 2015 Aug; 12():26. PubMed ID: 26292715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential cost-effectiveness of supervised injection facilities in Toronto and Ottawa, Canada.
    Enns EA; Zaric GS; Strike CJ; Jairam JA; Kolla G; Bayoumi AM
    Addiction; 2016 Mar; 111(3):475-89. PubMed ID: 26616368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility.
    Irwin A; Jozaghi E; Weir BW; Allen ST; Lindsay A; Sherman SG
    Harm Reduct J; 2017 May; 14(1):29. PubMed ID: 28532488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives on supervised injection facilities among service industry employees in New York City: A qualitative exploration.
    Wolfson-Stofko B; Elliott L; Bennett AS; Curtis R; Gwadz M
    Int J Drug Policy; 2018 Dec; 62():67-73. PubMed ID: 30359875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential role of safer injection facilities in reducing HIV and hepatitis C infections and overdose mortality in the United States.
    Semaan S; Fleming P; Worrell C; Stolp H; Baack B; Miller M
    Drug Alcohol Depend; 2011 Nov; 118(2-3):100-10. PubMed ID: 21515001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Willingness to use a supervised injection facility among young adults who use prescription opioids non-medically: a cross-sectional study.
    Bouvier BA; Elston B; Hadland SE; Green TC; Marshall BD
    Harm Reduct J; 2017 Feb; 14(1):13. PubMed ID: 28219388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlates of public support toward federal funding for harm reduction strategies.
    Kulesza M; Teachman BA; Werntz AJ; Gasser ML; Lindgren KP
    Subst Abuse Treat Prev Policy; 2015 Jun; 10():25. PubMed ID: 26122408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The willingness of people who inject drugs in Boston to use a supervised injection facility.
    León C; Cardoso L; Mackin S; Bock B; Gaeta JM
    Subst Abus; 2018 Jan; 39(1):95-101. PubMed ID: 28799847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Science versus politics: the need for supervised injection facilities in Montreal, Canada.
    Jozaghi E
    Int J Drug Policy; 2012 Sep; 23(5):420-1. PubMed ID: 22818890
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessing support for supervised injection services among community stakeholders in London, Canada.
    Bardwell G; Scheim A; Mitra S; Kerr T
    Int J Drug Policy; 2017 Oct; 48():27-33. PubMed ID: 28666204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study.
    Marshall BD; Milloy MJ; Wood E; Montaner JS; Kerr T
    Lancet; 2011 Apr; 377(9775):1429-37. PubMed ID: 21497898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Ottawa, Canada.
    Jozaghi E; Reid AA; Andresen MA; Juneau A
    Subst Abuse Treat Prev Policy; 2014 Aug; 9():31. PubMed ID: 25091704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.